Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead
Alvogen Is Also In The Race To Launch US Lenalidomide In 2022
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
